Table 3 Satisfaction with medication using the SATMED-Q subscales at 6 and 12 months and PEMAT-A/V scores at 2 months and 4 months post-intervention

Gout storytelling

N = 152

Control

N = 154

Difference (95% CI)

p value

Estimate (95% CI)

Estimate (95% CI)

 Total score (0–100)

63.74 (59.01; 68.47)

66.28 (61.58; 70.98)

−2.54 (−9.21; 4.12)

0.45

 Undesirable side effects (0–100)

9.26 (8.55; 9.97)

9.56 (8.86; 10.27)

−0.30 (−1.30; 0.70)

0.55

 Treatment effectiveness (0–100)

4.55 (4.03; 5.08)

4.58 (4.06; 5.10)

−0.025 (−0.77; 0.72)

0.95

 Convenience of use (0–100)

7.59 (6.86; 8.31)

8.62 (7.89; 9.34)

−1.03 (−2.06; 0.00)

0.05

 Impact on daily living/activities (0–100)

7.57 (6.88; 8.27)

7.83 (7.14; 8.52)

−0.26 (−1.24; 0.72)

0.60

 Medical care (0–100)

5.28 (4.78; 5.78)

5.31 (4.81; 5.80)

−0.03 (−0.73; 0.68)

0.94

 Global satisfaction (0–100)

9.09 (8.42; 9.77)

9.18 (8.50; 9.85)

−0.08 (−1.04; 0.87)

0.86

 Total score (0–100)

62.16 (57.09; 67.23)

67.43 (62.39; 72.47)

−5.27 (−12.42; 1.88)

0.15

 Undesirable side effects (0–100)

8.95 (8.22; 9.68)

9.77 (9.05; 10.50)

−0.83 (−1.86; 0.21)

0.12

 Treatment effectiveness (0–100)

4.41 (3.91; 4.91)

5.12 (4.62; 5.61)

−0.71 (−1.41; 0.00)

0.05

 Convenience of use (0–100)

7.71 (6.99; 8.43)

8.39 (7.67; 9.11)

−0.68 (−1.70; 0.34)

0.19

 Impact on daily living/activities (0–100)

7.62 (6.92; 8.33)

8.08 (7.38; 8.79)

−0.46 (−1.45; 0.54)

0.37

 Medical care (0–100)

4.96 (4.45; 5.47)

5.25 (4.75; 5.76)

−0.29 (−1.01; 0.43)

0.43

 Global satisfaction (0–100)

8.62 (7.92; 9.31)

9.23 (8.54; 9.92)

−0.62 (−1.60; 0.37)

0.22

N (%)

N (%)

Difference (95% CI)

p value

SATMED-Q side effect—yes

 6 months

9 (7.2%)

10 (7.4%)

0.97 (0.38; 2.47)

0.95

 12 months

9 (7.6%)

5 (3.8%)

2.06 (0.67; 6.34)

0.21

PEMAT-A/V total

Estimate (95% CI)

Estimate (95% CI)

Difference (95% CI)

 Baseline

66.80 (64.85; 68.76)

65.61 (63.67; 67.55)

1.19 (−1.56; 3.95)

0.40

 2 months

76.23 (71.19; 81.28)

68.48 (63.47; 73.49)

7.75 (0.65; 14.86)

0.03

 4 months

64.64 (58.37; 70.91)

58.96 (52.72; 65.19)

5.68 (−3.16; 14.53)

0.21

PEMAT-A/V understandable subscale score

 Baseline

92.16 (89.90; 94.41)

91.26 (89.02; 93.50)

0.90 (−2.28; 4.07)

0.58

 2 months

84.16 (78.61; 89.71)

76.22 (70.71; 81.74)

7.94 (0.11; 15.76)

0.05

 4 months

71.66 (64.74; 78.58)

65.73 (58.86; 72.61)

5.93 (−3.83; 15.69)

0.24

PEMAT-A/V actionable subscale score

 Baseline

91.12 (88.10; 94.13)

88.64 (85.64; 91.63)

2.48 (−1.77; 6.73)

0.25

 2 months

83.72 (78.06; 89.37)

75.16 (69.54; 80.78)

8.55 (0.58; 16.53)

0.04

 4 months

69.57 (62.65; 76.49)

64.45 (57.57; 71.32)

5.12 (−4.63; 14.88)

0.30